Epothilones: Better or more of the same?

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3079-3081

  Sabbatini, Paul ^a   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ANTHRACYCLINE; BIOLOGICAL MARKER; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; TAU PROTEIN; TAXANE DERIVATIVE; TOPOTECAN; ANTINEOPLASTIC AGENT; TUBULIN MODULATOR;

ADVANCED CANCER; ALOPECIA; ASTHENIA; BREAST CANCER; CANCER THERAPY; CELL LINE; CELL PROLIFERATION; CORRELATION ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; EDITORIAL; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; METASTASIS; MICROTUBULE; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; CLINICAL TRIAL; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EPOTHILONES; HUMANS; NEOPLASMS; TUBULIN MODULATORS;

EID: 67650327601     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6481     Document Type: Editorial

References (22)

1. Morris PG, Fornier MN: Microtubule active agents: Beyond the taxane frontier. Clin Cancer Res 14:7167-7172, 2008
2. Ferlini C, Gallo D, Scambia G: New taxanes in development. Expert Opin Investig Drugs 17:335-347, 2008
3. Larkin JM, Kaye SB: Potential clinical applications of epothilones: A review of phase II studies. Ann Oncol 18:v28-34, 2007 (suppl 5)
4. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 272:2534-2541, 1997
5. Hari M, Loganzo F, Annable T, et al: Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 5:270-278, 2006
6. Aghajanian C, Burris HA 3rd, Jones S, et al: Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 25:1082-1088, 2007
7. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007
8. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007
9. Johnson JI, Decker S, Zaharevitz D, et al: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431, 2001
10. Dizon DS, Blessing JA, McMeekin DS, et al: Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group Trial 129-P. J Clin Oncol 27:3104-3108, 2009
11. Lincoln S, Blessing JA, Lee RB, et al: Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 88:277-281, 2003
12. Miller DS, Blessing JA, Lentz SS, et al: A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol 87:247-251, 2002
13. Muggia FM, Blessing JA, Sorosky J, et al: Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 20:2360-2364, 2002
14. Garcia AA, Blessing JA, Nolte S, et al: A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol 111:22-26, 2008
15. Bansal N, Yendluri V, Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8-13, 2009
16. Oda K, Stokoe D, Taketani Y, et al: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669-10673, 2005
17. ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al: Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: A phase I, open-label, dose-escalation study. J Clin Oncol 27:3097-3103, 2009
18. Zanotti KM, Belinson JL, Kennedy AW, et al: Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 79:211-215, 2000
19. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
20. Markman M, Hakes T, Barakat R, et al: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: Paclitaxel in refractory ovarian cancer. J Clin Oncol 14:796-799, 1996
21. Andre F, Hatzis C, Anderson K, et al: Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13:2061-2067, 2007
22. Giannakakou P, Sackett DL, Kang YK, et al: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125, 1997